Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a ...

ExpertPrinceton-based Novazyme Pharmaceuticals is being acquired by Cambridge, Massachusetts-based Genzyme. Novazyme will operate as part of Genzyme General (Nasdaq: GENZ). Genzyme expects that ...

X4 Pharmaceuticals is developing a line of small molecule CXCR4 antagonists - licensing its core technology from Genzyme.

Sanofi-Aventis is buying specialty drugmaker Genzyme for $20.1 billion, the latest example of a beleaguered pharmaceutical company snapping up high-priced biotech drugs to offset dwindling sales ...

Genzyme Corp. said it would spend $325 million up front in a licensing and investment pact with Isis Pharmaceuticals Inc., securing partial rights to a promising cholesterol-lowering drug that ...

French pharmaceutical firm Sanofi-Aventis threatened to take control of Genzyme's board if it doesn't approve an $18.5 billion hostile takeover offer.

Cambridge-based Genzyme Corp., which has operations in Central Massachusetts, has completed the sale of its pharmaceutical intermediates business to Germany's International Chemical Investors ...

“Some of us call it the Genzyme mafia because we’ve infiltrated so many corners of biotech,” joked CoLucid Pharmaceuticals chief executive Tom Mathers. John Tlumacki/Globe Staff/Globe Staff ...

Genzyme is a leading bio-pharmaceutical company based in Cambridge, Massachusetts. Its products address rare diseases, kidney disease, orthopedics, cancer, transplant and immune diseases, and ...

The Genzyme-SangStat announcement came six weeks after Idec Pharmaceuticals Corp. agreed to spend $6.4 billion to acquire rival Biogen Inc. Idec, based in San Diego, and Cambridge-based Biogen ...